Small Cap Biotechs Slammed by SVB Collapse
Small Cap Biotechs Slammed by SVB Collapse Small Cap biotechs have been hit hard and needs time to sort out. Momentum and sentiment in a risk-off mode. Opportunity to assess good stocks for longer term after seeing how they trade. Nothing like a banking crisis to start off a weekend. But maybe...
Healthcare Is Lagging but Biotech Offers Good Potential for Value and Trading…UPDATE-2 Sell Off Continues with SVB news
Update-2 3/9/23... Silicon Valley Bank Collapse triggers more selling in small cap biotechs.Sold XBI at $79 for 4% profit now at $75. Large cap biopharma holding up well in green. Jobs grew solidly but at a slower pace.So looking for a 25 bps rate increase. Risk off. Update-1 3/8/23...Sell-off...
SMID Life Science Stocks Update : The Momentum Run Is Over-Risk Off…Update-2 Bit of a Rally
Update-2 3/2 Better tape action today. Big winners: CRSP, CYRX, NTLA, NVTA, QDEL, PACB,SUPN. Review on Weekend. Cowen conference next week March 8 should help life science sector. Update-1 2/28 Risk Off when FED rules with rates rising. Equities fighting higher yields.Trading range S&P 500...
SMID Cap Life Science Update: Are You an Investor or Trader?
SMID Life Science Stocks: Investor or Trader? Despite choppy trading there is an upward tilt to life science stocks since 9/26/22 lows. Three stocks are strong holds: EVH,HOLX and QDEL. Can gene therapy break through in 2023? Our SMID (small and mid) life science portfolio had a good week...
Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers…Update-3 Healthcare gains, energy, techs lose…
2/17 Mid-day trading shows healthcare and biopharma gainers , tech losers as FEDspeak (Bullard, Nestor) reiterates rates rising juxtaposed with recession risk rising. Large cap winners: ABBV,AMGN, GILD, MRK etc. UNH up 1.38% XLV up holding above $130 November lows. 2/15 late day trading.........